NCT05156021View on ClinicalTrials.gov

A Study on the Treatment Strategy of NVG Secondary to PDR

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Neovascular GlaucomaProliferative Diabetic Retinopathy

Interventions

DRUG

anti-VEGF

To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation

Trial Locations (1)

Unknown

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine,, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT05156021 - A Study on the Treatment Strategy of NVG Secondary to PDR | Biotech Hunter | Biotech Hunter